1st Success Story
VESTECK, Inc. is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.
Their first product, the “Suture-Tight” nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients. The VESTECK catheter secures endovascular aortic repair grafts to the aorta, eliminating migration and leaks that lead to complex expensive repairs and even mortality.
RightAir develops portable breathing assistance devices enhanced by machine learning algorithms. Its first product Air-AD, is first-in-class, non-invasive and will bring dramatic improvement to the quality of life for Chronic Obstructive Pulmonary Disease (COPD) patients. The AIR-AD looks like a regular clothing vest, but it dramatically offloads work of breathing and reduces dynamic hyperinflation, allowing patients to increase their physical activity and stay out of the hospital.
Avisi’s mission is to restore health and promote vitality. Its product, the VisiPlate, aims to treat open-angle glaucoma with an ocular implant that’s designed to remove excess fluid from inside the eye by releasing pressures that damage the optic nerve. VisiPlate leverages an ultrathin nanoplate that is designed to achieve unprecedented strength and flexibility for its scale, while its unique multichannel design creates outflow redundancy, which may lead to sustained IOP control over time.
Winterlight’s mission is to improve the lives of people with dementia and psychiatric illness. To this end, the company has assembled a team of experts specialising in computational linguistics, cognitive neuroscience and machine learning, to develop a proprietary, tablet-based technology that assesses cognitive health (including memory, thinking, and reasoning) by analysing hundreds of language markers from short snippets of speech.
Chip Diagnostics is an emerging leader in exosome-based diagnostics, enabling minimally invasive disease detection, drug efficacy prediction and monitoring using a nanoscale liquid biopsy technique targeting extracellular vesicles. Their innovation unlocks the potential of liquid biopsy by fingerprinting diseases with organ-specific signatures, providing actionable clinical data to empower clinicians to diagnose earlier and choose more appropriate therapies, thus lengthening lives while reducing healthcare costs.
Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer. Linnaeus’ lead compound, LNS8801, is a first-in-class, orally bioavailable small molecule that is highly specific and potent agonist of the G-protein estrogen receptor (GPER). GPER is widely expressed on cancers and stimulating GPER stops cancers from proliferating, and makes them more visible to the immune system. Linnaeus is currently testing LNS8801 in its phase 1/2a adaptive-design clinical trial as a monotherapy and is also collaborating with Merck on a clinical trial to evaluate the combination of LNS8801 and Merck’s anti-PD-1 therapy, KEYTRUDA® in patients with selected advanced solid tumors.
MBF Therapeutics is an immunotherapeutic animal health company focused on the use of its innovative T-Max™ DNA vaccine platform to create disruptive products for infectious disease and cancer. Initial development is focused on highly efficacious, universal vaccines that prevent significant current and new infectious diseases in animals with translational opportunities in humans. MBFT has assembled an extensive technology platform including multiple check point inhibitors, immunomodulators, adjuvants and delivery systems that work in concert to modulate the immune system, stimulating a durable cell mediated effector and memory response against abroad range of pathogens and cancers. The current pipeline includes vaccines to address African Swine Fever, Porcine Respiratory & Reproductive Syndrome, Canine Multi-tumor sarcoma and Next Generation SARS CoV-2.
Roundtrip is the leading digital transportation marketplace for better health outcomes. The company provides a simple, comprehensive patient ride ordering software that makes available a community of ride providers who complete the transport. RoundTrip is built for healthcare professionals – care coordinators, social workers, nurses, and other transport requestors – and offers easy-to-use online and mobile platforms that connect patients with non-emergency medical transportation(NEMT). RoundTrip is leading the industry in reducing patient no-shows through improved ride management and they are changing how people manage their health in their everyday lives.
Slope helps Clinical Trials Operations teams make data-driven decisions that accelerate time-to-market for demanding studies. Clinical trial sponsors rely on efficient study, design, planning, and execution to get their drugs, devices, and diagnostics to market. Yet, activities throughout the supply chain such as procurement, sample collection, routing, chain of custody are informed by inaccurate models that rarely reflect reality, contributing to delays in research, schedule and threatening clinical data integrity. Slope’s technology-driven infrastructure solution addresses the operational problems and delays by automating the coordination of thousands of logistical transactions throughout the lifecycle of a study while gathering and recording relevant metadata. This ensures fully traceable chain of custody for all components needed in a study as they travel across a clinical trial’s supply chain.
Strella Biotech is an agricultural biotech startup building biosensors that can predict the ripeness of fruit. The gathered information is then used to optimize the supply chain, which in turn can minimize food waste. Strella offers Internet of Everything sensors that monitor packer storage rooms and provide inventory sequences based on maturity so the packer can distribute the most mature fruit to the supply chain first.